Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancer: Clinical Oncology/Epidemiology

Formestane is a selective inhibitor of oestrogen synthesis by aromatase enzymes and induces disease regression in breast cancer patients. This phase II randomised study was carried out to determine whether there were any differences in the effects of two different doses of formestane on oestradiol (...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	British journal of cancer 1994-07, Vol.70 (1), p.145-150
Hauptverfasser:	Bajetta, E, Zilembo, N, Buzzoni, R, Noberasco, C, Di Leo, A, Bartoli, C, Merson, M, Sacchini, V, Moglia, D, Celio, L, Nelli, P
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomedical and Life Sciences Biomedicine Cancer Research clinical-oncology-epidemiology Drug Resistance Epidemiology Molecular Medicine Oncology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!